LY4395089 / Eli Lilly - LARVOL DELTA

A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants (clinicaltrials.gov) - P1 | N=14 | Completed | Sponsor: Eli Lilly and Company | Recruiting ➔ Completed

Trial completion

A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants (clinicaltrials.gov) - P1 | N=14 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open

J6Z-MC-IIBD - A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohns Disease nJ6Z-MC-CD01 - A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohns Disease (clinicaltrialsregister.eu) - P1/2 | N=7 | Not yet recruiting | Sponsor: Eli Lilly & Co.

New P1/2 trial • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • GCG

A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants (clinicaltrials.gov) - P1 | N=14 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P1 trial

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • GCG

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis